After-Hours Gainers: VCYT, RIGL, NPCE, CDNA, And FBLG Post Notable Moves Following Q3 Results

Core Insights - Several healthcare and biotech companies experienced significant after-hours stock price increases following the release of strong third-quarter earnings and updated guidance for 2025 [1] Company Summaries - Veracyte Inc. (VCYT): - Stock surged 16.07% to $41.92 - Reported third-quarter net income of $19.1 million, a 26% increase year-over-year - Net earnings per share rose to $0.24, up $0.05, while non-GAAP EPS reached $0.51, an increase of $0.18 - Revenue totaled $131.9 million, reflecting 14% growth from $115.9 million in Q3 2024 [2][3] - Rigel Pharmaceuticals, Inc. (RIGL): - Stock jumped 23.33% to $35.00 - Posted third-quarter net income of $27.9 million, more than doubling from $12.4 million last year - Earnings per share came in at $1.46 versus $0.70 last year - Total revenue for the quarter reached $69.5 million [4][5] - NeuroPace, Inc. (NPCE): - Stock rose 16.28% to $10.93 - Reported a narrower net loss of $3.5 million compared to a $5.5 million loss in the same period last year - Revenue grew 30% year-over-year to $27.4 million, up from $21.1 million [6] - CareDx, Inc. (CDNA): - Stock gained 8.47% to $15.75 - Reported GAAP net income of $1.7 million, compared to a $10.6 million loss in the prior-year period - GAAP earnings per share reached $0.03, reversing a $0.20 loss per share last year - Revenue increased 21% to $100.1 million [7][8] - FibroBiologics, Inc. (FBLG): - Stock edged up 5.29% to $0.3443 - Experienced a modest after-hours gain despite a steep decline of over 17% during the regular session - No new financial disclosures were issued alongside the price movement [9]